Business Context and Reporting Period
Company: Athira Pharma, Inc. (Note: Input metadata referenced "Leonabio," but the filing text identifies the registrant as Athira Pharma, Inc., trading under symbol ATHA).
Reporting Period: Quarterly period ended September 30, 2024 (Form 10-Q).
Business Overview: Athira is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Following the announcement of topline results for its Phase 2/3 LIFT-AD trial of fosgonimeton (which did not meet primary endpoints), the Company paused further development of fosgonimeton and shifted its strategic focus to the clinical development of its next-generation candidate, ATH-1105, for the potential treatment of ALS. The Company is also exploring strategic alternatives to maximize stockholder value.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(28,741) | $(32,970) | $(81,937) | $(90,387) |
| Operating Expenses | $29,621 | $35,042 | $85,336 | $96,452 |
| Cash, Cash Equivalents & Investments | $68,856 | $90,584 | $68,856 (Sep 30, 2024) | $90,584 (Dec 31, 2023) |
| Accumulated Deficit | $(391,143) | $(281,921) | $(391,143) | $(281,921) |
| Net Cash Used in Operating Activities (9M) | $(71,157) | $(74,460) | $(71,157) | $(74,460) |
Liquidity: As of September 30, 2024, the Company had $68.9 million in cash, cash equivalents, and investments. Management estimates this is sufficient to fund operations for at least the next 12 months. The Company has an "at-the-market" (ATM) equity offering facility for up to $75.0 million, though no securities have been sold under this facility to date.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $4.2 million (13%) in Q3 2024 compared to Q3 2023, and by $8.5 million (9%) for the nine-month period. This improvement was driven by reduced operating expenses.
- Operating Expenses: Total operating expenses decreased by $5.4 million (15%) in Q3 and $11.1 million (12%) for the nine months ended September 30, 2024.
- R&D Expenses: Decreased by $9.3 million in Q3 and $8.8 million for the nine months. This was primarily due to a $10.7 million reduction in fosgonimeton program costs (clinical trial and manufacturing) and a $0.9 million reduction in preclinical costs, partially offset by $2.4 million in new costs for the ATH-1105 Phase 1 trial.
- Legal Expenses: A new line item of $4.1 million was recorded in Q3 2024 related to the Department of Justice investigation. There were no comparable legal expenses in Q3 2023.
- Other Income: Decreased by $1.2 million in Q3 and $2.5 million for the nine months, attributed to lower interest income and accretion on available-for-sale securities due to lower investment balances.
Guidance, Outlook, Risks, and Unusual Items
- Strategic Shift: The Company has paused development of fosgonimeton following the LIFT-AD trial results and is focusing resources on ATH-1105 (ALS). It is actively exploring strategic alternatives, including potential mergers, acquisitions, or asset sales.
- Workforce Reduction: On September 15, 2024, the Company committed to a restructuring involving the termination of approximately 70% of its workforce. Estimated costs are $2.8 million, with $2.3 million accrued as of September 30, 2024.
- Legal Contingencies:
- Securities Class Action: A $10.0 million settlement was finalized and approved by the court in November 2024. The Company has deposited $8.4 million into a restricted settlement fund and expects an insurance recovery of $1.6 million.
- Government Investigation: The Company is cooperating with a Department of Justice investigation regarding its relationship with Washington State University (WSU) and NIH grants. A $4.1 million legal expense was accrued in Q3 2024.
- Scientific Misconduct Allegations: An independent special committee found that the former CEO altered images in her doctoral dissertation and research papers. This poses risks to the Company's reputation, intellectual property (specifically the WSU dihexa patent), and ability to secure partnerships.
- Nasdaq Compliance: The Company received a deficiency notice from Nasdaq regarding the minimum $1.00 closing bid price requirement and the $50 million market value of listed securities requirement. Failure to regain compliance could result in delisting.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $68.9 million cash balance given the 70% workforce reduction and the pause in fosgonimeton development. Confirm the timeline for the next capital raise if the strategic review does not yield a transaction.
- Legal Settlement Finality: Confirm the disbursement of the $10.0 million securities class action settlement and the timing of the $1.6 million insurance recovery.
- DOJ Investigation Status: Monitor developments in the Department of Justice investigation regarding NIH grants and WSU relationships, as unfavorable resolution could materially impact operations.
- ATH-1105 Progress: Track the completion of the Phase 1 trial for ATH-1105 (expected by year-end 2024) and the initiation of patient dosing for ALS in 2025.
- Nasdaq Listing Status: Monitor the Company's efforts to regain compliance with Nasdaq listing standards to avoid delisting.
- Strategic Alternatives: Watch for announcements regarding the outcome of the strategic review process, including potential mergers, asset sales, or liquidation scenarios.